Tenovate: Advanced Topical Corticosteroid for Inflammatory Skin Conditions
| Product dosage: 15g | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 4 | $9.03 | $36.12 (0%) | 🛒 Add to cart |
| 5 | $8.60 | $45.15 $43.00 (5%) | 🛒 Add to cart |
| 6 | $8.46 | $54.18 $50.74 (6%) | 🛒 Add to cart |
| 7 | $8.11 | $63.21 $56.76 (10%) | 🛒 Add to cart |
| 8 | $7.74 | $72.24 $61.92 (14%) | 🛒 Add to cart |
| 9 | $7.26 | $81.27 $65.36 (20%) | 🛒 Add to cart |
| 10 | $7.05
Best per tube | $90.30 $70.52 (22%) | 🛒 Add to cart |
Tenovate (clobetasol propionate 0.05%) is a high-potency topical corticosteroid formulation designed for the short-term treatment of severe, resistant inflammatory dermatoses. As a Class I super-potent corticosteroid, it delivers rapid anti-inflammatory, antipruritic, and vasoconstrictive actions through targeted cutaneous application. Tenovate is indicated for conditions unresponsive to lower-potency corticosteroids, providing dermatologists with a powerful tool for managing stubborn flare-ups while minimizing systemic exposure. Its optimized vehicle systems ensure enhanced drug delivery and patient compliance through appropriate formulation selection (ointment, cream, lotion, or foam) based on lesion characteristics and anatomical site.
Features
- Contains clobetasol propionate 0.05% as the active pharmaceutical ingredient
- Available in multiple formulations: ointment (occlusive, for dry/thickened lesions), cream (versatile, for most areas), lotion (scalp and hairy areas), and foam (scalp psoriasis)
- Rapid cutaneous penetration with minimal systemic absorption when used appropriately
- Potent vasoconstrictive activity (demonstrated by McKenzie-Stoughton assay)
- Paraben-free formulations in most variants (check specific product information)
- Stabilized emulsion systems to maintain chemical integrity and consistency
- pH-balanced to minimize irritation risk while maximizing drug stability
Benefits
- Provides rapid relief from inflammation, itching, and erythema within 48-72 hours of initiation
- Effectively manages severe dermatoses that have proven resistant to lower-potency corticosteroids
- Reduces plaque elevation and scaling in psoriatic lesions through targeted antiproliferative action
- Minimizes systemic exposure compared to oral corticosteroids when used as directed
- Offers formulation flexibility to match specific lesion characteristics and anatomical sites
- Short treatment course (typically 2 weeks) reduces cumulative steroid exposure while maintaining efficacy
Common use
Tenovate is primarily prescribed for short-term management of severe corticosteroid-responsive dermatoses including plaque psoriasis (especially recalcitrant lesions), lichen planus, discoid lupus erythematosus, granuloma annulare, and severe atopic dermatitis. It is particularly valuable for managing hyperkeratotic lesions on elbows, knees, and palms/soles where enhanced penetration is required. Dermatologists may also utilize Tenovate for lichen simplex chronicus and severe contact dermatitis cases where intense anti-inflammatory action is necessary. Off-label uses may include certain autoimmune blistering disorders and keloid management, though these applications require careful risk-benefit assessment.
Dosage and direction
Apply a thin film of Tenovate to the affected area once or twice daily, depending on severity and physician recommendation. The total weekly dosage should not exceed 50 grams (or 50 mL for lotion/foam). For most adults, treatment duration is limited to 2 consecutive weeks, with re-evaluation required before continuation. Occlusive dressings may be used for limited periods for extremely resistant lesions but increase systemic absorption risk. Wash hands after application unless treating hands. For scalp application, part hair to apply directly to lesions. Avoid use on face, groin, axillae, or other intertriginous areas unless specifically directed by a physician.
Precautions
Use Tenovate with caution in patients with liver impairment, though systemic effects are uncommon with appropriate topical use. Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use, large surface area application, or use under occlusion. Avoid use in patients with compromised skin barrier (extensive erosion, ulceration) due to increased absorption risk. Use sunscreen on treated areas when exposed to sunlight due to potential photosensitivity. Pediatric patients require careful supervision due to increased surface area-to-body weight ratio and higher systemic absorption risk. Elderly patients may have thinner skin and require reduced frequency of application.
Contraindications
Tenovate is contraindicated in patients with hypersensitivity to clobetasol propionate or any formulation components. Avoid use in rosacea, perioral dermatitis, acne vulgaris, and cutaneous infections (viral, fungal, or bacterial) unless appropriately treated with antimicrobial therapy. Contraindicated for ophthalmic use due to risk of glaucoma and cataract formation. Not recommended during pregnancy unless potential benefit justifies potential risk to fetus (Category C). Avoid use in nursing mothers on breast tissue; systemic corticosteroids may secrete into breast milk.
Possible side effects
The most common local adverse reactions include burning, stinging, itching, and dryness at application site (occurring in approximately 5-10% of patients). Less frequently, patients may experience folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, or contact dermatitis. With prolonged use or inappropriate application, systemic effects may include HPA axis suppression (manifested as fatigue, weakness, nausea, hypotension), hyperglycemia, glucosuria, Cushing’s syndrome, or intracranial hypertension. Long-term use may cause skin atrophy, striae, telangiectasia, and purpura, particularly on thin-skinned areas.
Drug interaction
Formal drug interaction studies have not been conducted with topical corticosteroids. However, concomitant use with other topical products may increase systemic absorption or cause interaction at application site. Use caution when combining with other potentially hepatically metabolized drugs. No known interactions with systemic medications have been documented when used topically as directed, though patients on concurrent systemic corticosteroids require monitoring for additive effects.
Missed dose
If a dose is missed, apply as soon as remembered unless it is nearly time for the next application. Do not double the dose to make up for a missed application. Maintain regular application schedule; inconsistent application may reduce efficacy. If multiple doses are missed, contact prescribing physician for guidance on re-initiation strategy.
Overdose
Topical overdose may manifest as systemic corticosteroid effects including hypercortisolism and adrenal suppression. Symptoms may include weight gain, moon facies, hypertension, hirsutism, and hyperglycemia. Acute topical overdose requires discontinuation and symptomatic management. There is no specific antidote; treatment should be supportive and based on symptoms. In case of accidental ingestion, seek immediate medical attention as systemic effects may be severe.
Storage
Store Tenovate at controlled room temperature (20-25°C or 68-77°F). Keep tube tightly closed and away from excessive heat or direct sunlight. Do not freeze. Keep out of reach of children and pets. Discany product that has changed color, consistency, or shows signs of separation. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Tenovate is a prescription medication requiring proper diagnosis and supervision by a qualified healthcare provider. Individual results may vary based on condition severity, application technique, and patient-specific factors. Always follow your physician’s instructions regarding use, duration, and monitoring. Report any adverse reactions to your healthcare provider promptly.
Reviews
Clinical studies demonstrate Tenovate achieves complete clearance or marked improvement in 75-85% of plaque psoriasis patients within 2 weeks. Dermatologists consistently rate it as highly effective for resistant dermatoses, though emphasize the importance of appropriate patient selection and duration limitation. Patients report significant improvement in itching and scaling within the first week of treatment. The various formulations receive positive feedback for cosmetic acceptability and ease of application. Long-term safety data support its risk-benefit profile when used appropriately for short durations under medical supervision.